Contact Us
7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition

WeChat scan to contact the organizer immediately

Weibo
WeChat
7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition

You can share it to WeChat via the Qr code.

Events
7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition

Enter the applet sharing event using WeChat scan.

Event Background

In the context of being part of ICH, the biopharmaceutical industry in China has entered a new era with emerging challenges: how to develop the next generation of innovative therapeutic biologics to stand out from the competition? How to speed up from R&D to regulatory submission with differentiated product pipelines (antibodies, therapeutic vaccines, cell and gene therapy products, virus products)?How to make compliance with regulatory requirements when making bioprocess improvement changes? How to accelerate the clinical development of innovative biopharma and biosimilars? What factors should be considered in the mass production and plant construction of biopharma?

As the most influential annual biopharma event in China, the 7th BioCon 2020 will be held on July 7-9 in CECIS-Shanghai, with higher speaker quality, deeper insights, cutting-edge regulation interpretation, and real technical case studies from leading biopharma players. Comprehensive topics will cover from drug discovery to IND, from the laboratory test to industrialization, from preclinical development to clinical development, from process development to commercial production, from NDA to commercial launch . The event aims to build a professional platform for regulatory discussions, technical exchanges, product displays, project cooperation from China and overseas, hence helping industry players to succeed in the fast growing Chinese biopharmaceutical industry!


001.jpg

What’s New in BioCon 2020?

结构-02.png Interpreting the latest guidelines of global regulations and China's new policies to help biopharma companies to navigate in the changing
regulatory environment

结构-02.png Focusing on the development of hot product portfolios -- the next generation of polyclonal antibodies, ADC, nano-antibodies, cell therapy, oncolytic viruses, recombinmant proteins and etc. 

结构-02.png Sharing the best practices of global product submissions with multi-centerclinical trials worldwide

结构-02.png Analyzing the latest discoveries and achievements of combined therapy for cancer

结构-02.png Introducing the application of new antibody development platforms to improve R&D efficiency with lower cost 

结构-02.png Discussing the optimized bioprocess changing paths and the supervision of post-process changing requirements

结构-02.png Exploring cost-effective biopharma plant design and construction in compliance with GMP requirements

13+ Sub-Forums, Covering the Whole Biopharma Discovery and Development Cycle

结构en-02.jpg

Rewiew of BioCon
h-01.png            

BioCon China is dedicated to establishing a robust idea-exchanging and business-cooperating platform for global regulatory agencies, and worldwide leading biotech companies and Asian biopharmaceutical enterprises. In the previous activities, BioCon China has accumulated 4000+ global industrial participants, 320+ leading products, solution and service providers, and 450+ prominent speakers to join the annual grand events.

Biocon 2020 Speaker(Part)
  • Member of Chinese Academy of Engineering
  • Director of Quantitative Pharmacology of FDA
  • Director of Shanghai Institute of Immunology
  • Secretary of the Party Committee of institutes of biomedical sciences
  • researcher at the Institute of Microbiology, Chinese Academy of Sciences.
  • Director of the Research Center for Drug Safety Evaluation of Shanghai Institute of Medicine, Chinese Academy of Sciences
  • Director of the Nanoantibody Research Center of Guangxi Medical University and Vice President of the Affiliated Stomatological Hospital
  • CEO, Fosun Kite Biotechnology Co. Ltd
    Richard received degrees of B.S of Cell Biology from the University of Science & Technology of China, Ph.D. of Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, Cincinnati in the US. He obtained his postdoctoral training at the National Institutes of Health, Baltimore, USA. Richard now is the CEO of Fosun Kite Biotechnology . Taking a combined approach of internal R&D and external partnering/technology transfer, Fosun Kite is dedicated to the advancement of innovative cell therapy and its industrialization in China to benefit patients. Richard is very experienced in biopharmaceutical industry . Having spent close to 20 years in R&D and management positions in both the US and China, he has taken senior roles and increasing leadership responsibilities in Procter & Gamble Pharmaceutical, Bristol-Myers Squibb in the US, AstraZeneca Innovation Center and GSK R&D Center in China. Prior to Fosun Kite, Richard was the Chief Operation Officer of Cellular Biomedicine Group (NASDAQ: CBMG), where he was in charge of the company’s immunotherapy pipeline including manufacturing, clinical development and registration, and the stem cell business unit.
  • President of RemeGen
  • Co founder, Shanghai Henlius Biotech, Inc.
  • Chairman and CEO of PersonGen.Anke
  • Co-founder & Chief Scientific Officer, Nanjing Legend Biotechnology Co., Ltd

    Dr. Fan Xiaohu is a well-known expert in the field of Applied Immunology and gene therapy. In 2004, he made a major breakthrough in the basic research of the mechanism of children's blood group incompatibility with heart transplantation. In his original paper published by Nature Medicine, he clarified the mechanism of immune tolerance in the process of children's heart transplantation and demonstrated that infant patients need not consider A before transplantation. BO blood group matched. This achievement breaks the limitation of homogenous organ transplantation and greatly improves the chances of organ transplantation for children with diseases. Returning to China in 2014 and joining Kingsley Group, Kingsley subsidiary Nanjing Legendary Biology was founded in early 2015. Excellent R&D team was established and advanced CAR-T technology platform was independently developed. LCAR-B38M, the first product for the treatment of relapsed and refractory multiple myeloma, achieved international leading results. Since its use in clinical trials in 2016, 74 people have been treated, with a complete response rate of 75%. This product has won a strategic partnership agreement between Johnson & Johnson and Legend to develop the global market for this product. On March 8, 2018, LCAR-B38M products were awarded the first clinical trial approval of CAR-T cell drugs in China, which became an important milestone in the history of cell therapy drugs in China. On May 30, 2018, LCAR-B38M products were also approved by the US FDA for phase Ib/II clinical trials. In 2019, he was eligible for the EU EMA Priority Drug Review. At present, Legendary Biology has the world's largest cell drug research and development team, developed a large number of new CAR-T cancer treatment products and a number of innovative intellectual property platform technology.

  • President of R&D, I-Mab
    申华琼先后在东南大学临床医学专业及四川大学华西医学院获医学学士及硕士学位 ,并曾担任外科医生。后赴美深造获得印第安纳大学生命科学博士学位。经过住院医生资格论证及培训成为美国有处方权的执照医生并通过了美国精神心理学和神经病学委员会专科认证。申华琼博士曾在美国礼来,惠氏,辉瑞担任全球临床研发高管10 多年,回国后又加入恒瑞医药并帮助建立了创新药临床团队,成功开拓了在澳洲及美国的临床试验。她2015年加入强生,成为中国开发中心副总裁及总负责, 负责整个中国的注册试验及亚洲的创新项目。在她的带领下强生中国将多个新药成功上市。申华琼于2017年后期作为研发总裁和董事的资格加入天境生物科技(上海)有限公司。申华琼曾是印第安纳大学临床兼职教授。她还曾获得国际糖尿病基金会专项研究基金进行内分泌与代谢研究. 此后还从事了精神病药物学和临床药理学的博士后研究。2009及2010年,她连续两年被授予”美国最佳精神心理医生”的荣誉称号,还发表了30多篇学术论文。她被选为2014“国家千人计划创新人才” 并当选中国药物临床评价研究专业委员会第二届委员。她也曾当选RDPAC研发核心工作组的预备主席。新近更被北京大学聘为客座教授。
  • CEO of CarsGen
  • CEO of JW therapeutics
  • founder, chairman and CEO of GMaxBio
  • founder, chairman and CEO of StemiRNA
  • founder and CEO of SinoMab BioScience Limited
  • director of r&d and bioimmunology at sanofi (USA)
  • chairman and CEO of Ractigen
  • chairman and CEO of HangZhou DAC biotech
  • chairman of Binhui-biotech
  • CEO and CSO of Shenzhen immvira-theravir
  • CEO of KelunBiotech and vice President of sichuan kelun pharmaceutical research institute
  • co-founder and CEO of BJ Bioscience Inc
  • CMO of Zai Lab Limited
  • vice President of Innovent Bio
  • chairman and President of Ascom bio-pharmaceutical & Jianshun Bio
  • vice President and chief technology officer of ask-pharm
  • founder of Waterstone china
  • chief translational medicine officer of CStonePharma
  • senior vice President of Qianyan bio
  • chairman and CEO of MEDx (Suzhou) Translational Medicine Co.,Ltd
    张亚飞博士(美国辛辛那提大学博士)拥有30年的药物研发经验及转化医学和诊断行业经验,现任迈杰转化医学研究(苏州)有限公司董事长和CEO。之前相继担任美国方达医药中国总经理和集团资深副总裁、诺华中国研发中心部门总监、美国OSI医药集团部门总监以及美国辉瑞研发中心经理。张博士是全球生命科学和医疗健康产业领域华人精英组织百华协会 (Bayhelix)的一员,也是江苏省生物技术协会副理事长,同时是中国生物工程协会精准医疗和伴随诊断专业委员会发起者之一及副主任委员。 荣获了园区创业创新领军人才,金鸡湖双百人才计划, 江苏省双创人才,江苏省海外高层次人才和江苏省优秀企业家称号。
  • Founder & CEO, JADE BioMedical
    千人计划企业创新专家,出生于上海,曾就学于复旦大学,之后获美国加州大学伯克利分校细胞和分子生物学博士学位。在博士后培训期间及之后,林博士对基础型和转化型癌症进行过深入研究。在过去15年里,她的职业生涯主要聚焦于化学、生产和控制尤其是质量管理等方面。她曾在基因泰克/罗氏担任多种质量管理领导的岗位职责,包括临床研发阶段的QA,QC部门,以及罗氏全球商业化生物产品技术转移、年度产品质量回顾等;之后,林博士在加州的拜耳医药生物技术分部担任质量总监,全面负责所有临床开发阶段中质量体系及产品质量。林博士曾参与全球领先的单抗产品上市工作,包括Avastin, Perjeta, Kavoltry。林博士在欧美亚同行中享有很好的声誉,活跃与世界级的专业会议讲台。2015年初,林博士归国先后担任两家中国知名生物制药企业高管,负责GMP合规与质量管理。2017年5月,林博士创立苏州驾玉生物医药有限公司,专注生物制药行业的质量管理及检测承包服务。
  • general manager of Genoimmune
  • deputy general manager of Hengrui Medicine
  • vice President of Gracell Bio
  • senior vice President of Teruisi Pharm
  • vice President of quality science , chuang sheng group
  • general manager of Shanghai Tofflon
  • SVP, Head of CMC, Harbour BioMed
  • founder of Romics
  • Executive Director of Biomarker, Henlius
    邹灵龙博士为上海复宏汉霖生物技术股份公司执行总监,领导PK、PD、免疫原性和生物标志物的分析。他毕业于中国科学院上海药物所,在美国贝勒医学院完成博士后训练,曾就职于Tanox(Genentech) Inc.和梯瓦制药公司。在工业界18年,他参与了几十个生物药的开发,其中6个生物药已在欧美获批上市,1个生物类似药汉利康®也获得中国药监局的批准上市。
  • VP, BIORAY LABORATORIES Inc
    Dr. Zhang liang graduated from Shanghai Institute of Biochemistry and Cell Biology, CAS. He used to be the project leader of drug research and development in Shanghai Haiyan Medical Technology CO. LTD. (Yangtze River Pharmaceutical Group). Currently, he is responsible for the development and production of cell therapy as the vice president of BIORAY LABORATORIES Inc. He has rich experience in new drug development, compliance and application, he also has extensive experience in cell therapy technology and translational systems development.
  • President of research ,PreGene
  • senior director of Henlius
  • technical director of PersonGen.Anke
  • senior medical director, Alphamab
  • senior director of quality assurance at 3s-guojian
  • general manager of Obio
  • senior medical officer of PersonGen.Anke
  • Institute of Microbiology, Chinese Academy of Sciences
  • research and development director of Edigene-A Genome Editing Company
  • quality director of Wuxi shengji pharmaceutical
  • Testimonials Testimonials
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    Partners
    Co-organizers
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    Supporters
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    Media Partners
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    7th BioCon China 2020 & Biotechnology Equipment and  Reagent Exhibition
    Retrieve E-tickets
    Please enter the ticket recipient's email or cell phone
    Retrieve